The therapeutic efficacy of any antiviral whose purpose is to reduce viral replication requires maintaining a efficacious concentration of the ligand at its putative target for an extended period of time. Conservatively, this period should ideally be of long duration relative to a virus's replication time to reach peak viral load. An interval typically measured in days in the case of SARS-CoV-2 infection in humans. However, polyphenolic compounds' potential for efficacy for any particular pathology is criticized due to a prima facie poor pharmacokinetic ADMET profile. Consider, for example, diosmetin. A primary intermediate metabolite of the pharmaceutical formulation known as Daflon (comprised of 90% diosmin, and 10% hesperidin, diosmetin, linarin, and isorhoifolin), it and similarly proportioned formulations are prescribed in many countries around the world for chronic venous insufficiency (CVI).